BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Novartis  Europharm  Limited  submitted  on  1  July  2004  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Xolair,  in  accordance  with  the 
centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 
2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. Tomas Salmonson 
Co-Rapporteur:  Dr. Gonzalo Calvo Rojas 
Scientific Advice: 
The  applicant  received  Scientific  Advice  from  the  CHMP  on  25  July  2002.  The  Scientific  Advice 
pertained to clinical aspects of the dossier. 
Licensing status: 
Xolair has been given a Marketing Authorisation in Australia on 31 May 2002 and USA on 20 June 
2003. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 1st July 2004.  
The procedure started on 19 July 2004. 
The Applicant provided updated clinical information on 21 September 2004 after uncovering an 
error in counting historical exacerbations in a pivotal study (2306). 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 11 October 
2004. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 12 
October 2004. 
The BWP issued a report to the CHMP on 5 November 2004.  
During  the  meeting  on  16-18  November  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  18 November 2004. 
During the meeting on 16-18 November 2004, the CHMP agreed on a GCP inspection request 
which was revised at December 2004 CHMP meeting. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  10 
February 2005. 
The integrated GCP inspection report was circulated to Rapporteurs on 11 March 2005 and to 
all CHMP members in the March Post-mail. It was also sent to the applicant on 15 March 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  21 March 2005. 
During  the  CHMP  meeting  on  18-21  April  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The Applicant submitted the responses to the List of Outstanding Issues on 10 May 2005. 
During the CHMP meeting on 23-26 May 2005, the CHMP agreed on a list of questions to be 
addressed by experts. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on  30 May 2005. 
On  8  June  2005,  an  Ad-hoc  expert  group  meeting  was  held  at  the  EMEA  to  answer  to  the 
above-mentioned list of questions. The Applicant was invited to present their view during this 
meeting. The report of the Ad-Hoc expert group meeting was sent for information to the CHMP 
and the Applicant on 16 June 2005. 
The Rapporteurs circulated an update of Joint Assessment Report on the applicant’s responses 
to the List of Outstanding Issues to all CHMP members on  16 June 2005. 
1/2 
©EMEA 2005 
 
 
• 
• 
• 
During  the  CHMP  meeting  on  20-23  June  2005,  the  applicant’s  oral  explanation  on  the 
outstanding issues before the CHMP was cancelled.  
During the meeting on 25-28 July 2005, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Xolair  on  27  July  2005.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 26 July 2005. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 25 October 2005. 
2/2 
©EMEA 2005 
 
